Biotech and Pharmaceuticals Pharmaceuticals

More

  • Dow component Johnson & Johnson—the first major health care company to report earnings this quarter—posted weaker-than-expected quarterly revenue on Tuesday. Mike Weinstein, managing director and senior medical technology analyst at JPMorgan, offered his analysis of JNJ.

  • Stocks fell on Tuesday after the Dow closed near the 10,000 mark on Monday. What is the best move for investors now? Roy Williams, CEO of Prestige Wealth Management, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment insights.

  • Dendreon is growing in more ways than one. At a time when so many drug companies are letting people go, Dendreon is on a hiring binge to ramp up for the anticipated launch of its prostate cancer drug Provenge. But it's also expanding its board of directors.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    A “ton of upside” is in store for this stock, Cramer says. Find out why.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    It’s all about the earnings, he says. These are the companies you need to watch.

  • With $137 billion worth of brand name drugs going generic over the next several years, the recession and the looming threat of healthcare reform a lot of people have been running scared about what it all means for pharma. So, surprise, surprise! This morning IMS Health, which closely monitors the industry, came out with its annual forecast and it now says the American drug market is going to grow this year instead of shrink.

  • rats_200.jpg

    I’ve said it before, and I know it’s a bad cliché (is there such a thing as a good cliché?), but I learn something new almost every day. Today, my lesson came in the form of an eye-catching research note out of Leerink Swann, which specializes in covering healthcare-related companies and stocks.

  • Pharmacist wearing face mask

    Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.

  • Stocks rebounded Monday as investors' waning enthusiasm got a jolt from a report that showed the services sector has begun to expand. Plus, there was some bargain hunting after the market's two-week decline.

  • Stocks rebounded Monday as investors' waning enthusiasm got a jolt from a report that showed the services sector has begun to expand. Plus, there was some bargain hunting after the market's two-week decline.

  • Stocks advanced Monday after a better-than-expected reading on the service sector. Plus, investors did some bargain hunting after a two-week decline.

  • If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.

  • US stock index futures pointed higher Monday after two tough weeks for Wall Street.

  • Stocks ended lower Friday as a dismal jobs report capped a string of disappointing economic reports this week, which cast doubt on the recovery. It was the market's second straight down week in which stocks have lost more than 3 percent.

  • Stocks tried to push higher Friday as the dollar's retreat helped the market but investors remained worried about the recovery in the wake of some disappointing economic reports.

  • Stocks opened lower Friday after disappointing reports on jobs and manufacturing.

  • Stock index futures plunged as September nonfarm payroll declines were far worse than Wall Street estimates.

  • Shares of generic drugmaker Mylan dropped for the third straight session yesterday but drew heavy upside options activity.

  • New York Public Information Campaign Warns of Swine Flu

    The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.

  • Sequenom

    It's the equivalent of slipping a press release with negative news under the door at the close of business on a Friday. But after the closing bell on Yom Kippur, when many people including me were trying to give up food and tweeting for a day, Sequenom tossed a grenade.